Gerich J E
Mayo Clin Proc. 1985 Jul;60(7):439-43. doi: 10.1016/s0025-6196(12)60866-0.
Despite the fact that sulfonylurea orally administered hypoglycemic agents have been used in the treatment of non-insulin-dependent diabetes mellitus for almost 30 years, only recently have their mechanisms of action been delineated. In addition to the four agents previously available, two so-called second-generation agents were approved last year for use in the United States. The indications, contraindications, and guidelines for the use of these agents, as well as their mechanisms of action and the differences among them, are reviewed in this article. When appropriately used, these agents can provide a safe and effective adjunct to diet therapy in the management of patients with non-insulin-dependent diabetes mellitus and thus should be considered as an alternative to insulin therapy for such patients.
尽管口服磺脲类降糖药用于治疗非胰岛素依赖型糖尿病已近30年，但直到最近其作用机制才得以阐明。除了先前已有的四种药物外，两种所谓的第二代药物去年在美国被批准使用。本文对这些药物的适应证、禁忌证、使用指南及其作用机制和相互间的差异进行了综述。合理使用时，这些药物可作为饮食治疗的安全有效辅助手段，用于管理非胰岛素依赖型糖尿病患者，因此应被视为这类患者胰岛素治疗的替代方案。
